ArticleHepatology international2025
Reply to: A commentary on "Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis".
Jae-Young Kim et al.PubMed ↗Publisher ↗
No numbers read from the abstract.